Clinical trial
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
NCT05906576 is registered in ClinicalTrials.gov with Taizhou Mabtech Pharmaceutical Co.,Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
- Lead sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- September 21, 2023
- Completion date
- February 28, 2027
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.